1Addario GD, Pintilie M, Leighl NB, et al. Platinum based versus Non-platinum-based chemotherapy in advanced non-small-cell lung eaneer:A meta-analysis of the published literature [J].J Clin Oncol,2005,23 ( 13 ) : 2926 - 2935.
2Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small-cell lung cancer [ J ]. Pharmacogenomics, 2003,3 ( 6 ) :763 - 780.
3Brundage MD, Davies D, Mackillop WJ, et al. Prognostic factors in non-small cell lung cancer: a decade of progress[J]. Chest,2002,122( 3 ) : 1037 - 1057.
4Rosell R,Lord RV,Tareon M, et al. DNA repair and eisplatin resistance in non-small-cell lung cancer[ J ]. Lung cancer,2002,38(3) :217 -227.
5Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer[ J ]. Cancer Control, 2003,10 (4) :297 - 305.
6Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy[J]. Lung Cancer,2004,44(3):311 -316.
7Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[ J ]. Chest ,2005,127 ( 3 ) :978 - 983.
8Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer[ J ]. Clin Cancer Res ,2002,8 ( 7 ) :2286 - 2291.
9Rosell R, Cobo M, lsLa D, et al. ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin(cis) or gemcitabine (gem) in stage Ⅳ non-small-cell lung cancer (NSCLC) patients (p) [J]. J CLin Oncol,2005,23( suppl) :621.
10Soria J, Haddad V, Olaussen KA, et al. Immunohistochemical staining of the Excision Repair Cross-Complementing 1 ( ERCC1 )protein as predictor for benefit of adjuvant chemotherapy (CT) in the International Lung Cancer Trial (IALT)[J]. J Clin Oncol,2006,24 (suppl) , Abstract :7010.
